Earns royalties, milestones and upfront payments by out-licensing its approved CXCR4 antagonist motixafortide (APHEXDA) to commercial partners, while funding in-licensed oncology and rare-disease development programs such as GLIX1 for glioblastoma.
Geographic Exposure
United States100%
IsraelN/A
Revenue Drivers
Motixafortide out-licensing royalties
Royalties from licensee sales of APHEXDA in stem cell mobilization
CORE100%
End Markets
Ayrmid Pharma Ltd.
Gloria Biosciences / Hong Seng Technology (HST)
Pharmaceutical licensees
Specializations
CXCR4 antagonist peptide therapeuticsStem cell mobilization for autologous transplantation in multiple myelomaMotixafortide in pancreatic cancer (PDAC) and solid tumorsGLIX1 oral small molecule targeting DNA damage response via TET2 restorationGlioblastoma (GBM) drug developmentSuccess-based, back-ended in-licensing deal structures
